SCHEMBL15617596

SCHEMBL15617596

COc1ccc(C(CO)c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.58
GPR88 Q9GZN0 1/20 0.55
CNR2 P34972 2/20 0.53
CNR1 P21554 1/20 0.53
PBRM1 Q86U86 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CA4 P22748 1/20 0.50
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CRHBP P24387 1/20 0.49
CYP2C19 P33261 1/20 0.49
CRHR2 Q13324 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128925 0.94 ABCB11 (0.52) ACP3GPR88CNR2CNR1L3MBTL1
SCHEMBL3941057 0.85 ABCB11 (0.49) ACP3GPR88L3MBTL1KMT2ACYP1A2
SCHEMBL19984896 0.85 TDP1 (0.51) GPR88CNR2L3MBTL1KMT2AMEN1
SCHEMBL17295959 0.83 MTNR1A (0.58) L3MBTL1LMNAHTTKMT2AMEN1
SCHEMBL13871997 0.82 CYP17A1 (0.64) ACP3CNR2CNR1PBRM1L3MBTL1
SCHEMBL2065584 0.80 HTR2A (0.64) ACP3CNR2CNR1PBRM1CA4
SCHEMBL7001179 0.80 ACP3 (0.53) ACP3CNR2CNR1PBRM1L3MBTL1
SCHEMBL7411961 0.80 ACP3 (0.53) ACP3CNR2CNR1PBRM1L3MBTL1
SCHEMBL193835 0.80 HTR2A (0.52) L3MBTL1LMNACYP2D6TDP1
SCHEMBL28489153 0.79 FFAR1 (0.61) ACP3CNR2CNR1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306986-B1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES PROLYNX LLC (US) 2018-03-21 EP disclosed
US-9387254-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX LLC (US) 2016-07-12 US disclosed
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES PROLYNX LLC 2014-10-02 US disclosed
US-8680315-B2 Prodrugs and drug-macromolecule conjugates having controlled drug release rates PROLYNX, LLC (US) 2014-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296476-A1 PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES ABCB1, ABCB11, DNPEP ACP3 203/4885GPR88 2472/4885CNR2 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.